Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment publishing date : 2021 - 06 - 01 save search
Stemming from SEC Guidance Concerning Balance Sheet Treatment of Warrants, Tailwind Acquisition Corp. Announces Receipt of NYSE Continued Listing Standard Notice
Published: 2021-06-01 (Crawled : 22:00) - globenewswire.com
TWND 4 | $0.16 6025.0% 75K
|
Finance
|
| O: 0.0%
H: 0.0%
C: 0.0%
treatment acquisition acquisition corp
Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Barth Syndrome
Published: 2021-06-01 (Crawled : 21:00) - prnewswire.com
MITO | $0.32 0.25%
|
Health Technology
|
| O: 38.62%
H: 4.48%
C: -11.94%
treatment europe drug iot syndros elamipretide designation
Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
Published: 2021-06-01 (Crawled : 21:00) - globenewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.85%
H: 0.37%
C: 0.02%
treatment fda fda approval children approval psoriasis plague
Growing Array of Pharmacological Interventions in Bronchitis Treatment Market to Boost Chronic Bronchitis Care, Market Valuation to Rise at CAGR of 3.6% from 2018 to 2026: TMR
Published: 2021-06-01 (Crawled : 15:00) - prnewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.7%
H: 0.02%
C: -0.99%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.13%
H: 0.08%
C: -1.21%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.93%
H: 0.09%
C: -0.87%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.65%
H: 0.04%
C: -1.56%
treatment growing
Medtronic Announces Scientific Data Presentations at the 14th International Conference on Advanced Technologies & Treatments for Diabetes
Published: 2021-06-01 (Crawled : 15:00) - biospace.com/
MDT | $81.29 0.89% 0.0% 5.2M
|
Health Technology
|
| O: 1.17%
H: 0.04%
C: -2.56%
presentation diabetes treatment conference
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Published: 2021-06-01 (Crawled : 14:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.53%
H: 0.03%
C: -2.72%
treatment fda therapy breakthrough therapy grant designation
Viracta Therapeutics Announces the Initiation of NAVAL-1, a Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma
Published: 2021-06-01 (Crawled : 14:00) - biospace.com/
VIRX | $0.831 -5.57% -5.9% 84K
|
Manufacturing
|
| O: -3.66%
H: 6.3%
C: -0.9%
treatment positive trial
Adamis Pharmaceuticals Provides Business UpdateNDA for ZIMHI™ submitted to the FDA; Phase 2/3 clinical trial preparation initiated for Tempol for treatment of COVID-19
Published: 2021-06-01 (Crawled : 13:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 0.54%
H: 3.87%
C: 1.01%
covid treatment fda phase 2 phase 2/3 trial initiated
CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis
Published: 2021-06-01 (Crawled : 12:00) - biospace.com/
CTIC | $9.09 0.05% 11M
|
Health Technology
|
| O: 5.86%
H: 2.77%
C: -1.19%
treatment biopharma fibrosis granted grant
BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1
Published: 2021-06-01 (Crawled : 12:00) - globenewswire.com
BBIO | $25.43 1.44% 1.42% 1.1M
|
Health Technology
|
| O: 0.88%
H: 1.61%
C: 1.09%
treatment fda fda fast track fast track fast track designation designation pharma
Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Published: 2021-06-01 (Crawled : 12:00) - globenewswire.com
PRTK | $2.23 0.0% 4.8M
|
Health Technology
|
| O: 6.48%
H: 12.99%
C: 12.3%
treatment fda acquired fda approval approval
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
Published: 2021-06-01 (Crawled : 11:00) - investor.alkermes.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.29%
H: 0.28%
C: -0.95%
ALKS | $24.26 0.79% 0.78% 1.2M
|
Health Technology
|
| O: 0.79%
H: 1.4%
C: 1.31%
treatment fda schizophrenia fda approval approval
Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis
Published: 2021-06-01 (Crawled : 11:00) - biospace.com/
AKBA | $1.365 0.37% 0.37% 2.1M
|
Health Technology
|
| O: 5.41%
H: 2.16%
C: -7.84%
new drug disease treatment fda fda acceptance anemia drug kidney dialysis
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Published: 2021-06-01 (Crawled : 09:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 0.42%
H: 2.35%
C: 1.95%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 1.79%
H: 0.03%
C: -3.56%
treatment potential dermatitis phase 3 atopic dermatitis
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.